Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company whose news flow is closely tied to the progress of its Superkine pipeline. Company updates consistently highlight advances in MDNA11, a long-acting IL-2 Superkine in the Phase 1/2 ABILITY-1 trial for advanced solid tumors, as well as developments in MDNA113, a tumor-anchored and conditionally activated PD-1 x IL-2 bifunctional Superkine, and bizaxofusp (MDNA55), an IL-4 Empowered Superkine for recurrent glioblastoma.
On this page, readers can follow MDNAF news related to clinical data readouts, new trial announcements and corporate milestones. Recent releases describe updated MDNA11 results in monotherapy and in combination with pembrolizumab, including activity in checkpoint inhibitor-resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H tumors, as well as plans to complete enrollment in ABILITY-1 and prepare for potential registrational studies. News also covers the NEO-CYT neoadjuvant trial in high-risk, surgically resectable Stage III melanoma, sponsored by Fondazione Melanoma Onlus, which will evaluate MDNA11 in combination with nivolumab with or without ipilimumab.
Investors and clinicians can also track preclinical and non-human primate updates for MDNA113, including safety and pharmacodynamic findings that Medicenna reports as supporting its advancement toward first-in-human trials. Additional news items address partnering efforts and data presentations for bizaxofusp in recurrent glioblastoma, patent issuances protecting IL-2 and IL-4 Superkine assets, and participation in scientific and investor conferences.
By reviewing the MDNAF news feed, users can see how Medicenna communicates new clinical results, outlines expected milestones, and provides context on the scientific rationale behind its Superkine programs, while also including standard cautions about the risks and uncertainties inherent in drug development.
Medicenna (OTCQX: MDNAF) provided a 2026 outlook and program updates focused on MDNA11, MDNA113 and bizaxofusp. ABILITY-1 has enrolled >110 safety-evaluable patients (102 efficacy-evaluable) across 29 cancer types; biologically effective dose range was set at 60–120 µg/kg with no dose-limiting toxicities. Key efficacy: monotherapy expansion cohorts (n=21) showed 50% ORR in 2L/3L patients and 42% ORR post-ICI failure; overall monotherapy (n=55) ORR was 19% (2L/3L) and 24% (post-ICI). MDNA113 NHP data tolerable to 30 mg/kg; IND planned H2 2026. Cash runway into Q3 2026.
Medicenna (OTCQX: MDNAF) presented updated Phase 1/2 ABILITY-1 data for MDNA11 at ESMO-IO Congress on Dec 10, 2025. Key findings at the Biological Effective Dose Range (60–120 µg/kg Q2W/Q3W) include monotherapy ORR of 42% and DCR of 83% in patients treated after progression on immune checkpoint inhibitors, ORR of 38% in checkpoint-resistant melanoma, and ORR of 22% in MSI-H tumors. Combination with KEYTRUDA showed ORR/DCR of 50%/75% in MSS endometrial cancer and 25%/88% in TMB-H tumors. Median OS was longer in patients achieving disease control (monotherapy mOS 120.2 vs 28.6 weeks; combination mOS not reached vs 26 weeks). Safety was manageable with >90% Grade 1–2 TRAEs and no DLTs up to 120 µg/kg.
Medicenna (OTCQX: MDNAF; TSX: MDNA) will host a live webinar on December 10, 2025 at 08:30 AM ET to discuss updated clinical data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as a monotherapy and in combination with pembrolizumab. The event features presentations by company management and the presenting Principal Investigator, followed by commentary from key opinion leaders and live Q&A.
Presenters include Dr. Fahar Merchant (President and CEO), Dr. Arash Yavari (Director of Clinical Strategy) and Dr. André Mansinho (presenting Principal Investigator). Registration is required and a replay will be available on Medicenna’s website after the event.
Medicenna (OTCQX: MDNAF, TSX: MDNA) reported Q2 fiscal 2026 results and a corporate update on Nov 13, 2025. Key clinical milestones include an MDNA11 data presentation at ESMO IO Congress on Dec 10, 2025 and a randomized neoadjuvant NEO-CYT trial in Italy (up to 12 centres) testing MDNA11 with nivolumab ± ipilimumab. MDNA113 is in non-human primate studies with IND-enabling work planned H1 2026 and a first-in-human trial targeted H2 2026. Six patents were issued or allowed across US, Japan, Canada and Australia. Cash was $15.7M, providing runway into at least mid-2026.
Medicenna (OTCQX: MDNAF) announced a randomized, investigator‑initiated neoadjuvant trial named NEO-CYT to test MDNA11 with nivolumab ± ipilimumab in high‑risk, surgically resectable Stage III melanoma.
The study is sponsored by Fondazione Melanoma Onlus at Istituto Nazionale Tumori ‘G. Pascale’; Medicenna will supply study drug. Primary endpoint is Major Pathologic Response (MPR). Company noted prior deep, durable responses in the ongoing ABILITY‑1 study and expects cash & equivalents to fund operations into at least mid‑2026.
Medicenna (OTCQX: MDNAF, TSX: MDNA) will present updated clinical data for MDNA11 from the Phase 1/2 ABILITY-1 study at the ESMO Immuno-Oncology Congress 2025 in London on December 10-12, 2025. The presentation by Dr. André Mansinho covers an interim analysis of MDNA11 as a monotherapy and in combination with pembrolizumab in advanced solid tumors.
Presentation title: ABILITY-1, a phase 1/2 of MDNA11, a next-generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis. A copy of the presentation will be posted on the company’s Events and Presentations page after the congress.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) announced participation in three upcoming investor and industry events in late 2025 to present its Superkines pipeline and engage partners and investors.
- Planet MicroCap Showcase: TORONTO 2025 – Oct 22, 2025; presentation and one-on-ones; 1:30 PM ET; webcast available.
- BIO-Europe 2025 – Nov 3–5, 2025; Vienna; one-on-one partnering meetings.
- Oppenheimer Miami Oncology Summit – Nov 6, 2025; Miami; panels and networking.
The events are described as opportunities to highlight ongoing clinical trials, discuss the company’s immunotherapy programs, and meet potential partners and investors.
Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company, announced its participation in the upcoming ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 8-9, 2025 at the Metropolitan Club in New York City.
Dr. Fahar Merchant, President and CEO of Medicenna, will engage in one-on-one and small group meetings with institutional investors, providing detailed insights into the company's development of Superkines for treating cancer, autoimmune, and inflammatory diseases.
Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company specializing in Superkines development, held its annual shareholders meeting on September 25, 2025. The meeting saw a 55.75% turnout of issued and outstanding common shares, with all nominated directors successfully elected with overwhelming support, each receiving over 98.8% approval.
Notable changes include Dr. John H. Sampson's departure from the board, though he will continue as a clinical advisor. The election results demonstrated strong shareholder confidence, with key figures like Dr. Fahar Merchant and Ms. Karen Dawes receiving 99.25% and 99.35% of votes respectively.
Medicenna Therapeutics (OTCQX:MDNAF), a clinical-stage cancer immunotherapy company specializing in Superkines development, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
Dr. Fahar Merchant, President and CEO, will deliver a presentation on September 9th, 2025, at 2:30 PM EST at the Lotte New York Palace Hotel. The presentation will be available via webcast, with a 90-day replay period accessible through Medicenna's investor relations website.
FAQ
What is the current stock price of Medicenna Therapeutics (MDNAF)?
What is the market cap of Medicenna Therapeutics (MDNAF)?
